French drugmaker Sanofi and its U.S. partner Regeneron Pharmaceuticals could win U.S. approval for their keenly awaited new eczema drug dupilumab, seen by analysts as a potential $3 billion-a-year seller, by next March.
Sanofi badly needs new products to make up for flagging sales in its diabetes business, where its top-seller Lantus faces growing competition.
Source: Reuters
Filed Under: Drug Discovery
